Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc (FULC) Covered Calls
Fulcrum Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 87.70%, high versus the past year. FULC's highest covered call setup is the $4.00 strike expiring Jun 17, 2027, sorted by theoretical annualized return. It's 7.82% out of the money with 213 days to expiration, a 9.16% return until expiration, and a 15.70% theoretical annualized return. Across the setups shown, annualized returns run from 15.70% to 15.70% at strikes between $4.00 and $4.00, with 213 to 213 days to expiration, as of Nov 16, 2026.
Read more
Running FULC covered calls helps you generate income from Fulcrum Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best FULC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If FULC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling FULC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given FULC covered call is worth writing.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
| 2027-06-17 | 213 | 4.00 | 7.82 | 0.05 | 1.35 | 34.00 | 9.16 | 15.70 | -1.35 | +0.57 | 43 | 1.30 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank87.70% High
- Market cap (M$)286
- 52 weeks high-76.18%
- 52 weeks low32.51%
- Analyst recommendationHold
3.00 - Target price$4.00
6.67% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-08-05
- P/E—
- Future P/E—
- EPS (ttm)-1.04
- EPS growth next 5 years47.58%
As of Nov 17, 2026